HP Hepion Pharmaceuticals, Inc. Stock: price and management transactions · United States · SEC (Form 4)Follow the Hepion Pharmaceuticals, Inc. share price and the full directors' dealings record of the company, a listed equity based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Market capitalisation: €6.8m. The latest transaction was reported on 12 August 2026 (Acquisition). Among the most active insiders: LoPriore Vincent S. The full history is openly available.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 12 August 2026
All Executives15 Thresholds0 Prospectus0 Other0
Declarations 15 total
▲ Executive Chairman · Executives · 3 Aug 2026
2,000,000 shares @ US$0.05 5.72% mcap 13.4% of flow Common Stock SEC:0001493152-26-037489:1
Canonical exit: 1 Nov 2026 (T+90) ▲ Director · Executives · 3 Aug 2026
2,000,000 shares @ US$0.05 5.72% mcap 67.1% of flow Common Stock SEC:0001493152-26-037493:0
Canonical exit: 1 Nov 2026 (T+90) ▲ Director · Executives · 3 Aug 2026
500,000 shares @ US$0.05 1.43% mcap 100.0% of flow Common Stock SEC:0001493152-26-037500:0
Canonical exit: 1 Nov 2026 (T+90) ▲ Executive Chairman · Executives · 3 Aug 2026
$400,000 ★ Strong · 70SEC ↗ 8,000,000 shares @ US$0.05 22.89% mcap 53.7% of flow Common Stock SEC:0001493152-26-037489:0
Canonical exit: 1 Nov 2026 (T+90) ▲ Interim CEO · Executives · 3 Aug 2026
$100,000 ★ Strong · 70SEC ↗ 2,000,000 shares @ US$0.05 5.72% mcap 67.1% of flow Common Stock SEC:0001493152-26-037496:0
Canonical exit: 1 Nov 2026 (T+90) ▲ Chief Operating Officer · Executives · 3 Aug 2026
2,000,000 shares @ US$0.05 5.72% mcap 67.1% of flow Common Stock SEC:0001493152-26-037490:0
Canonical exit: 1 Nov 2026 (T+90) ▲ Executive Chairman · Executives · 21 Apr 2026
$200,000 ★ Strong · 72SEC ↗ 5,000,000 shares @ US$0.04 10.76% mcap 80.0% of flow Common Stock, par value $0.0001 per share SEC:0001493152-26-019029:0
Canonical exit: 20 Jul 2026 (T+90) ▲ Director · Executives · 21 Apr 2026
1,250,000 shares @ US$0.04 2.69% mcap 100.0% of flow Common Stock, par value $0.0001 per share SEC:0001493152-26-019028:0
Canonical exit: 20 Jul 2026 (T+90) ▲ Interim CEO · Executives · 21 Apr 2026
1,250,000 shares @ US$0.04 2.69% mcap 100.0% of flow Common Stock, par value $0.0001 per share SEC:0001493152-26-019027:0
Canonical exit: 20 Jul 2026 (T+90) ▲ Executive Chairman · Executives · 21 Apr 2026
1,250,000 shares @ US$0.04 2.69% mcap 20.0% of flow Common Stock, par value $0.0001 per share SEC:0001493152-26-019029:1
Canonical exit: 20 Jul 2026 (T+90) ▲ Director · Executives · 21 Apr 2026
1,250,000 shares @ US$0.04 2.69% mcap 100.0% of flow Common Stock, par value $0.0001 per share SEC:0001493152-26-019202:0
Canonical exit: 20 Jul 2026 (T+90) ▲ Director · Executives · 24 Nov 2023
2,500 shares @ US$3.09 56.4% of flow Common Stock SEC:0001104659-23-121427:0
Canonical exit: 22 Feb 2024 (T+90) ▲ Director · Executives · 15 Sept 2023
1,000 shares @ US$5.82 100.0% of flow Common Stock SEC:0001104659-23-102209:0
Canonical exit: 14 Dec 2023 (T+90) ▲ CEO and Director · Executives · 18 Sept 2023
1,600 shares @ US$5.60 50.8% of flow Common Stock SEC:0001104659-23-101784:0
Canonical exit: 17 Dec 2023 (T+90) ▲ CEO,CSO and Director · Executives · 15 Sept 2023
1,600 shares @ US$5.40 49.2% of flow Common Stock SEC:0001104659-23-101391:0
Canonical exit: 14 Dec 2023 (T+90) 关于 Hepion Pharmaceuticals, Inc. Hepion Pharmaceuticals, Inc. 是一家生物制药公司，专注于开发肝病治疗方法。它主要致力于创新药物的研发。